Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

The conversation discusses using high molecular weight hyaluronic acid after microneedling to form a protective barrier, though it's considered expensive and offers marginal improvement. Users share experiences with different microneedling tools like derma rollers, dermastamps, and Dr. Pen, with some opting not to use any products on the scalp.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

People discussed which is better for hair loss treatment between a dermaroller and a dermastamp, concluding that a dermastamp is better. They also mentioned that a dermaroller can be used for beard growth.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

A user purchased an expensive hair loss treatment called Follicopeptide, which many others in the conversation believe to be a scam, suggesting instead the use of proven treatments like minoxidil and finasteride. Some users report positive effects from Follicopeptide, but skepticism remains high due to lack of transparency about its ingredients and the company's credibility.

Platelet-rich plasma (PRP) therapy for hair loss is expensive, painful, and often ineffective, with mixed reviews on its benefits. Alternatives like minoxidil, finasteride, and hair transplants are suggested as more reliable options.

CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.

The conversation is about adding dermarolling to a hair loss treatment routine. The user seeks recommendations for dermarollers, stamps, or pens, emphasizing the importance of quality and proper cleaning.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

The user has been using finasteride, minoxidil, and a derma stamp for 3 months with significant improvement. They are now adding ketoconazole to their routine.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

The conversation discusses the steps for microneedling, specifically differentiating between medical needling (0.5-1.5mm) and cosmetic needling (0.3mm). It emphasizes the importance of cleaning and disinfecting before microneedling, regardless of needle length.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The conversation is about the preference for using a derma stamp over a derma roller for hair loss treatment, with users discussing its efficiency, needle material, replacement frequency, and personal experiences. Specific treatments mentioned include microneedling with a derma stamp.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Carnosic acid in rosemary extract may enhance skin repair and promote hair follicle regeneration. It could be used alone or with verteporfin for scarless healing after dermal wounding.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

The user compared microneedling with a stamp versus a pen, finding the Dr. Pen more effective and easier to use than the Bioneedle stamp. They also mentioned using oral minoxidil for hair loss treatment.

User started using Pantostin Alfatradiol after watching haircafe on YouTube and noticed thicker hair. They wonder why it's not more popular, as it's a 5α-reductase inhibitor with a different mechanism than minoxidil.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.